Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 336

1.

Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.

Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A.

Eur J Endocrinol. 2005 Jan;152(1):61-6.

2.

Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.

Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A.

Neuroendocrinology. 2006;83(3-4):249-57. Epub 2006 Oct 13. Review.

PMID:
17047390
3.

Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.

Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R.

J Clin Endocrinol Metab. 2006 Jan;91(1):85-92. Epub 2005 Nov 1.

PMID:
16263832
4.

Octreotide as primary therapy for acromegaly.

Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.

J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40.

PMID:
9745397
5.

111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.

Legovini P, De Menis E, Billeci D, Conti B, Zoli P, Conte N.

J Endocrinol Invest. 1997 Jul-Aug;20(7):424-8.

PMID:
9309542
7.

Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.

Plöckinger U, Quabbe HJ.

Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493. Epub 2005 Apr 4.

PMID:
15806331
8.

Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register.

Petersenn S, Buchfelder M, Reincke M, Strasburger CM, Franz H, Lohmann R, Quabbe HJ, Plöckinger U; Participants of the German Acromegaly Register.

Eur J Endocrinol. 2008 Nov;159(5):525-32. doi: 10.1530/EJE-08-0498. Epub 2008 Aug 28.

9.

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.

Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA.

Clin Endocrinol (Oxf). 2008 Jun;68(6):970-5. Epub 2007 Nov 19.

PMID:
18031313
10.

Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.

Waśko R, Ruchała M, Sawicka J, Kotwicka M, Liebert W, Sowiński J.

J Endocrinol Invest. 2000 Jan;23(1):12-8.

PMID:
10698045
11.

[Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry].

Jaquet P, Cortet-Rudelli Ch, Sassolas G, Morange-Ramos I, Chanson P, Brue T, Andrieu JM, Beckers A, Bertherat J, Borson-Chazot F, Brassier G, Caron P, Cogne M, Cottier JP, Delemer B, Dufour H, Enjalbert A, Figarella-Branger D, Gaillard R, Gueydan M, Jan M, Kuhn JM, Raingeard I, Regis J, Roger P, Rohmer V, Sadoul JL, Saveanu A, Tabarin A, Travers N, Trouillas J; French Acromegly Registry.

Ann Endocrinol (Paris). 2003 Dec;64(6):434-41. Review. French.

PMID:
15067248
12.

Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.

Bianchi A, Valentini F, Iuorio R, Poggi M, Baldelli R, Passeri M, Giampietro A, Tartaglione L, Chiloiro S, Appetecchia M, Gargiulo P, Fabbri A, Toscano V, Pontecorvi A, De Marinis L.

J Exp Clin Cancer Res. 2013 Jun 21;32:40. doi: 10.1186/1756-9966-32-40.

13.

Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.

Cannavò S, Squadrito S, Curtò L, Almoto B, Trimarchi F.

Horm Metab Res. 2001 Oct;33(10):618-24.

PMID:
11607883
14.

Medical therapy for acromegaly.

Newman CB.

Endocrinol Metab Clin North Am. 1999 Mar;28(1):171-90. Review.

PMID:
10207690
15.

Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.

Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R.

J Clin Endocrinol Metab. 2009 Oct;94(10):3746-56. doi: 10.1210/jc.2009-0941. Epub 2009 Jul 21.

PMID:
19622615
16.

Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.

Carlsen SM, Svartberg J, Schreiner T, Aanderud S, Johannesen O, Skeie S, Lund-Johansen M, Fougner SL, Bollerslev J; POTA study group.

Clin Endocrinol (Oxf). 2011 Jun;74(6):736-43. doi: 10.1111/j.1365-2265.2011.03982.x.

PMID:
21521254
17.

Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.

Lucas T, Astorga R, Catalá M; Spanish Multicentre Lanreotide Study Group on Acromegaly.

Clin Endocrinol (Oxf). 2003 Apr;58(4):471-81.

PMID:
12641631
18.

Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.

De Marinis L, Mancini A, Bianchi A, Gentilella R, Valle D, Giampietro A, Zuppi P, Anile C, Maira G, Giustina A.

Metabolism. 2002 May;51(5):616-21.

PMID:
11979395
19.

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.

Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK, Aydin Y, Guler S.

Pituitary. 2012 Sep;15(3):398-404. doi: 10.1007/s11102-011-0335-y.

20.

Long-term primary medical therapy with somatostatin analogs in acromegaly.

Su DH, Liao KM, Chen HW, Chang TC.

J Formos Med Assoc. 2006 Aug;105(8):664-9.

Items per page

Supplemental Content

Write to the Help Desk